vs
Side-by-side financial comparison of Esperion Therapeutics, Inc. (ESPR) and Global Net Lease, Inc. (GNL). Click either name above to swap in a different company.
Esperion Therapeutics, Inc. is the larger business by last-quarter revenue ($168.4M vs $117.0M, roughly 1.4× Global Net Lease, Inc.). On growth, Esperion Therapeutics, Inc. posted the faster year-over-year revenue change (143.7% vs -15.1%). Over the past eight quarters, Esperion Therapeutics, Inc.'s revenue compounded faster (10.6% CAGR vs -11.1%).
Esperion Therapeutics, Inc. is a publicly traded American pharmaceutical company focused on the development of bempedoic acid, an orally available small molecule designed to lower elevated levels of LDL-C. The company is headquartered in Ann Arbor, Michigan.
Global Net Lease, Inc. is a publicly traded real estate investment trust that acquires, owns and manages a diversified portfolio of commercial real estate assets under long-term net lease contracts. Its property portfolio spans North America and Europe, covering industrial, office, retail and other key sectors, serving tenants across multiple industries to deliver consistent long-term returns for shareholders.
ESPR vs GNL — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $168.4M | $117.0M |
| Net Profit | — | $48.2M |
| Gross Margin | — | — |
| Operating Margin | 50.6% | 94.7% |
| Net Margin | — | 41.2% |
| Revenue YoY | 143.7% | -15.1% |
| Net Profit YoY | — | 838.7% |
| EPS (diluted) | $0.32 | $0.14 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $168.4M | $117.0M | ||
| Q3 25 | $87.3M | $121.0M | ||
| Q2 25 | $82.4M | $124.9M | ||
| Q1 25 | $65.0M | $132.4M | ||
| Q4 24 | $69.1M | $137.8M | ||
| Q3 24 | $51.6M | $138.7M | ||
| Q2 24 | $73.8M | $145.5M | ||
| Q1 24 | $137.7M | $147.9M |
| Q4 25 | — | $48.2M | ||
| Q3 25 | $-31.3M | $-60.1M | ||
| Q2 25 | $-12.7M | $-24.1M | ||
| Q1 25 | $-40.5M | $-189.4M | ||
| Q4 24 | — | $-6.5M | ||
| Q3 24 | $-29.5M | $-65.6M | ||
| Q2 24 | $-61.9M | $-35.7M | ||
| Q1 24 | $61.0M | $-23.8M |
| Q4 25 | 50.6% | 94.7% | ||
| Q3 25 | -11.4% | -11.7% | ||
| Q2 25 | 8.6% | 33.9% | ||
| Q1 25 | -34.0% | -21.1% | ||
| Q4 24 | -6.4% | 40.8% | ||
| Q3 24 | -31.0% | 9.3% | ||
| Q2 24 | 3.5% | 42.6% | ||
| Q1 24 | 52.5% | 38.6% |
| Q4 25 | — | 41.2% | ||
| Q3 25 | -35.9% | -49.7% | ||
| Q2 25 | -15.4% | -19.3% | ||
| Q1 25 | -62.2% | -143.0% | ||
| Q4 24 | — | -4.7% | ||
| Q3 24 | -57.2% | -47.3% | ||
| Q2 24 | -83.9% | -24.5% | ||
| Q1 24 | 44.3% | -16.1% |
| Q4 25 | $0.32 | $0.14 | ||
| Q3 25 | $-0.16 | $-0.32 | ||
| Q2 25 | $-0.06 | $-0.16 | ||
| Q1 25 | $-0.21 | $-0.87 | ||
| Q4 24 | $-0.14 | $-0.08 | ||
| Q3 24 | $-0.15 | $-0.33 | ||
| Q2 24 | $-0.33 | $-0.20 | ||
| Q1 24 | $0.34 | $-0.15 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $167.9M | $180.1M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $-302.0M | $1.7B |
| Total Assets | $465.9M | $4.3B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $167.9M | $180.1M | ||
| Q3 25 | $92.4M | $165.1M | ||
| Q2 25 | $86.1M | $144.8M | ||
| Q1 25 | $114.6M | $147.0M | ||
| Q4 24 | $144.8M | $159.7M | ||
| Q3 24 | $144.7M | $127.2M | ||
| Q2 24 | $189.3M | $122.2M | ||
| Q1 24 | $226.6M | $131.9M |
| Q4 25 | $-302.0M | $1.7B | ||
| Q3 25 | $-451.4M | $1.7B | ||
| Q2 25 | $-433.5M | $1.8B | ||
| Q1 25 | $-426.2M | $1.9B | ||
| Q4 24 | $-388.7M | $2.2B | ||
| Q3 24 | $-370.2M | $2.3B | ||
| Q2 24 | $-344.2M | $2.4B | ||
| Q1 24 | $-294.3M | $2.5B |
| Q4 25 | $465.9M | $4.3B | ||
| Q3 25 | $364.0M | $4.8B | ||
| Q2 25 | $347.1M | $5.0B | ||
| Q1 25 | $324.0M | $5.8B | ||
| Q4 24 | $343.8M | $7.0B | ||
| Q3 24 | $314.1M | $7.3B | ||
| Q2 24 | $352.3M | $7.6B | ||
| Q1 24 | $373.1M | $8.0B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $45.2M | $222.8M |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | 0.0% | — |
| Cash ConversionOCF / Net Profit | — | 4.62× |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $45.2M | $222.8M | ||
| Q3 25 | $-4.3M | $56.0M | ||
| Q2 25 | $-31.4M | $52.0M | ||
| Q1 25 | $-22.6M | $59.2M | ||
| Q4 24 | $-35.0M | $299.5M | ||
| Q3 24 | $-35.3M | $62.1M | ||
| Q2 24 | $-7.2M | $70.4M | ||
| Q1 24 | $53.8M | $92.2M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | $-35.5M | — | ||
| Q2 24 | $-7.3M | — | ||
| Q1 24 | $53.8M | — |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | -68.7% | — | ||
| Q2 24 | -9.9% | — | ||
| Q1 24 | 39.0% | — |
| Q4 25 | 0.0% | — | ||
| Q3 25 | 0.0% | — | ||
| Q2 25 | 0.0% | — | ||
| Q1 25 | 0.0% | — | ||
| Q4 24 | 0.0% | — | ||
| Q3 24 | 0.3% | — | ||
| Q2 24 | 0.1% | — | ||
| Q1 24 | 0.1% | — |
| Q4 25 | — | 4.62× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | 0.88× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ESPR
| Collaboration Revenue | $124.7M | 74% |
| Products | $43.7M | 26% |
GNL
| Industrial And Distribution Segment | $56.0M | 48% |
| Office Segment | $30.8M | 26% |
| Single Tenant Retail Segment | $30.2M | 26% |
